NXT2 (Gene)

Organism:

Homo sapiens

Synonyms:ENTREZ:55916, HGNC:18151, MIM:300320, NM_001242617, NM_001242618, NM_018698, NP_001229546, NP_001229547, NP_061168, NXT2, P15-2, XM_011530989, XM_017029648, XP_011529291, XP_016885137, nuclear transport factor 2 like export factor 2

Omim:OMIM:300320

Id:ENSG00000101888

Hgnc:HGNC:18151

Entrez:55916

Ensembl:ENSG00000101888

Description:nuclear transport factor 2 like export factor 2

The protein encoded by this gene contains a nuclear transport factor 2 (NTF2) domain, which plays an important role in the trafficking of macromolecules, ions, and small molecules between the cytoplasm and nucleus. This protein may also have a role in mRNA nuclear export. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jun 2011]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View NXT2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with NXT2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using NXT2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for NXT2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with NXT2.

Results found

Linked to

	Label	Description
	GSE240439 decitabine 1 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE216273 GSE216292 palbociclib 14 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE255432 7 V 3 IMEGLIMIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE163862 2 V 3 CISPLATIN MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE82110,GSE82299 1 V 0 ACRIFLAVINE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 3 v 11 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 2 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE176366 vincristine 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS

GSE240439 decitabine 1 v 2 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273,GSE216292 14 V 6 PALBOCICLIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE216273 GSE216292 palbociclib 14 v 1 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE255432 7 V 3 IMEGLIMIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE195663 cisplatin 0 v 3 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE163862 2 V 3 CISPLATIN MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE82110,GSE82299 1 V 0 ACRIFLAVINE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 3 v 11 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE111247 temozolomide LN-308 2 v 6 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE176366 vincristine 3 v 2 human dn

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.